Mostrar el registro sencillo del ítem

dc.contributor.authorCairat, Manon
dc.contributor.authorSánchez Pérez, María José 
dc.date.accessioned2022-05-04T11:55:22Z
dc.date.available2022-05-04T11:55:22Z
dc.date.issued2022-04-18
dc.identifier.citationCairat, M... [et al.]. Circulating inflammatory biomarkers, adipokines and breast cancer risk—a case-control study nested within the EPIC cohort. BMC Med 20, 118 (2022). [https://doi.org/10.1186/s12916-022-02319-y]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/74698
dc.descriptionThis work was funded by the French National Cancer Institute (grant number 2016-128) and the World Cancer Research Fund (grant number 2017/1614). Manon Cairat was supported by a PhD fellowship from la Ligue Nationale Contre le Cancer. The coordination of EPIC is financially supported by International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education Nationale, Institut National de la Sante et de la Recherche Medicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition PotsdamRehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS) -Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucia, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology -ICO (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skane and Vasterbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (1000143 to EPICNorfolk; MR/M012190/1 to EPIC-Oxford). (United Kingdom). The funders were not involved in designing the study; collecting, analyzing or interpreting the data; or in writing or submitting the manuscript for publication.es_ES
dc.description.abstractBackground: Inflammation has been hypothesized to play a role in the development and progression of breast cancer and might differently impact breast cancer risk among pre and postmenopausal women. We performed a nested case-control study to examine whether pre-diagnostic circulating concentrations of adiponectin, leptin, c-reactive protein (CRP), tumour necrosis factor-α, interferon-γ and 6 interleukins were associated with breast cancer risk, overall and by menopausal status. Methods: Pre-diagnostic levels of inflammatory biomarkers were measured in plasma from 1558 case-control pairs from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. We used conditional logistic regression to estimate the odds ratios (ORs) of breast cancer at blood collection, per one standard deviation increase in biomarker concentration. Results: Cases were diagnosed at a mean age of 61.4 years on average 8.6 years after blood collection. No statistically significant association was observed between inflammatory markers and breast cancer risk overall. In premenopausal women, borderline significant inverse associations were observed for leptin, leptin-to-adiponectin ratio and CRP [OR= 0.89 (0.77–1.03), OR= 0.88 (0.76–1.01) and OR= 0.87 (0.75–1.01), respectively] while positive associations were observed among postmenopausal women [OR= 1.16 (1.05–1.29), OR= 1.11 (1.01–1.23), OR= 1.10 (0.99–1.22), respectively]. Adjustment for BMI strengthened the estimates in premenopausal women [leptin: OR = 0.83 (0.68– 1.00), leptin-to-adiponectin ratio: OR = 0.80 (0.66–0.97), CRP: OR = 0.85 (0.72–1.00)] but attenuated the estimates in postmenopausal women [leptin: OR = 1.09 (0.96–1.24), leptin-to-adiponectin ratio: OR = 1.02 (0.89–1.16), CRP: OR = 1.04 (0.92–1.16)]. Conclusions: Associations between CRP, leptin and leptin-to-adiponectin ratio with breast cancer risk may represent the dual effect of obesity by menopausal status although this deserves further investigation.es_ES
dc.description.sponsorshipInstitut National du Cancer (INCA) France 2016-128es_ES
dc.description.sponsorshipWorld Cancer Research Fund International (WCRF) 2017/1614es_ES
dc.description.sponsorshipLigue nationale contre le canceres_ES
dc.description.sponsorshipWorld Health Organizationes_ES
dc.description.sponsorshipNIHR Imperial Biomedical Research Centre (BRC)es_ES
dc.description.sponsorshipDanish Cancer Societyes_ES
dc.description.sponsorshipLigue nationale contre le canceres_ES
dc.description.sponsorshipInstitut Gustave Roussyes_ES
dc.description.sponsorshipMutuelle Generale de l'Education Nationalees_ES
dc.description.sponsorshipInstitut National de la Sante et de la Recherche Medicale (Inserm)es_ES
dc.description.sponsorshipDeutsche Krebshilfees_ES
dc.description.sponsorshipHelmholtz Associationes_ES
dc.description.sponsorshipFederal Ministry of Education & Research (BMBF)es_ES
dc.description.sponsorshipFondazione AIRC per la ricerca sul cancroes_ES
dc.description.sponsorshipConsiglio Nazionale delle Ricerche (CNR)es_ES
dc.description.sponsorshipDutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Fundses_ES
dc.description.sponsorshipDutch Prevention Fundses_ES
dc.description.sponsorshipNetherlands Organization for Scientific Research (NWO)es_ES
dc.description.sponsorshipWorld Cancer Research Fund (WCRF), Statistics Netherlandses_ES
dc.description.sponsorshipHealth Research Fund (FIS) -Instituto de Salud Carlos III (ISCIII)es_ES
dc.description.sponsorshipCatalan Institute of Oncology -ICO (Spain)es_ES
dc.description.sponsorshipSwedish Cancer Societyes_ES
dc.description.sponsorshipSwedish Research Counciles_ES
dc.description.sponsorshipEuropean Commissiones_ES
dc.description.sponsorshipCounty Councils of Skanees_ES
dc.description.sponsorshipVasterbotten (Sweden)es_ES
dc.description.sponsorshipCancer Research UK 14136 C8221/A29017es_ES
dc.description.sponsorshipUK Research & Innovation (UKRI)es_ES
dc.description.sponsorshipMedical Research Council UK (MRC)es_ES
dc.description.sponsorshipEuropean Commission 1000143 MR/M012190/1es_ES
dc.language.isoenges_ES
dc.publisherBMCes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectBreast canceres_ES
dc.subjectInflammation es_ES
dc.subjectBiomarkerses_ES
dc.subjectMenopausal statuses_ES
dc.subjectAnthropometry es_ES
dc.titleCirculating inflammatory biomarkers, adipokines and breast cancer risk—a case-control study nested within the EPIC cohortes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1186/s12916-022-02319-y
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 3.0 España